Indonesia

BMI Core View: Private healthcare spending as a percentage of total healthcare expenditure in emerging markets will decrease over the medium term. Governments in these countries increasingly... 2011-05-09

BMI View: Merck KGaA's Indonesian subsidiary's sales growth of 5.9% (in local currency) in 2010 pales in comparison to the double digit increase in sales between 2006-2009 and in comparison... 2011-04-19

BMI View: We welcome the Indonesian Health Ministry's focus on improving the country's business environment in order to encourage multinational drugmakers to set up local manufacturing... 2011-02-11

BMI View: While there are numerous factors inhibiting multinational investment in the Indonesian pharmaceuticals and healthcare market, including as a small market size compared with... 2011-02-09

BMI View: While Indonesia's pharmaceutical market is small compared with its Asia Pacific neighbours, BMI believes factors such as the annual growth the market, combined with rising... 2011-02-08

Developed state underperformance remains a recurring theme within our Industry analysis. We remain concerned about US labour market weakness and its impact, particularly on consumer... 2010-09-28

BMI Core View: Drugmakers based in emerging markets will increasingly produce hard-to-manufacture pharmaceuticals. Firms in developing countries enjoy low operating costs but have traditionally... 2010-07-19